Plant Health Care PLC Pilot production of PREtec peptides
09 Septiembre 2019 - 1:01AM
RNS Non-Regulatory
TIDMPHC
Plant Health Care PLC
09 September 2019
9 September 2019
PLANT HEALTH CARE plc
("Plant Health Care" or the "Company")
Pilot production of PREtec peptides
Plant Health Care(R) , a leading provider of novel
patent-protected biological products to global agriculture markets,
is pleased to provide the following update in relation to the
commercialisation of PREtec peptides, in preparation for commercial
launches.
Highlights:
- An agreement has been signed with CSL Behring Fermentation
Facility at Pennsylvania State University, to scale up for
commercial production of PREtec peptides
- Following the recent exciting field trials results with PHC279
in Brazil soybeans, industry response has been very positive
- The Company intends to commercialise PREtec peptides in
markets worth more than $5 billion, starting with PHC279
- The first launches are likely to be into corn and soybeans in
the USA and in soybeans in Brazil for the control of Asian Soybean
Rust
Plant Health Care is developing novel peptide products from the
PREtec (Plant Response Elicitor) platform. These products stimulate
the plant to defend itself from stress, such as disease and
drought, leading to better quality and higher yield at harvest.
Derived from natural proteins, PREtec peptides are a novel,
environmentally friendly approach to protecting crops and
increasing yields, compatible with mainstream agricultural
practices.
The Company intends to commercialise PREtec peptides in markets
worth more than $5 billion, starting with PHC279, an Innatus 3G
peptide. The first launches are likely to be into corn and soybeans
in the USA and in soybeans in Brazil for the control of Asian
Soybean Rust. Field trials have shown compelling results in
improved disease control and better yields from seed treatment with
PHC279.
The Company has developed low cost production methods for PREtec
peptides at laboratory scale in our own facilities in Seattle,
based on fermentation. The next stage in moving to commercial
production is to establish a pilot plant, which will scale up those
methods in larger vessels. The pilot plant will refine the
Company's production methods, which will then be used in the
manufacture of peptides for commercial sales.
The Company is pleased to announce that an agreement has been
reached with the CSL Behring Fermentation Facility at Penn State
University. The University is providing excellent facilities for
optimising production methods, focusing initially on PHC279,
including production of initial commercial quantities. We
anticipate this project will take less than 12 months, after which
the Company expects to contract full scale manufacture with a
commercial manufacturer.
Dr Christopher Richards, Executive Chairman and Interim CEO of
Plant Health Care, said: "We are delighted to have concluded this
agreement with an outstanding institution. The pilot plant further
builds our first-class capability to commercialise PHC279 directly
to distribution in the USA and Brazil. Industry response in Brazil
to our recent excellent field trials results has been most
encouraging as we move towards the first product launches."
Dr Nigel Deighton, Director of Research Instrumentation at the
Huck Institutes of the Life Sciences, which operates the CSL
Behring Fermentation Facility said "It is wonderful that our
outreach to industrial partners continues to grow; our Institute
and donors alike are delighted to make this exciting
connection."
For further information, please contact:
Plant Health Care plc
Chris Richards, Executive Chairman and Interim CEO Tel: +44 7795 294 300
Jeff Tweedy, COO Tel: +1 919 926 1600
Arden Partners plc - Broker and Nomad
John Llewellyn-Lloyd / Dan Gee-Summons (Corporate Finance) Tel: +44 (0) 20 7614 5900
Fraser Marshall (Equity Sales)
Company website: www.planthealthcare.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRACKADDPBKDCCK
(END) Dow Jones Newswires
September 09, 2019 02:01 ET (06:01 GMT)
Plant Health Care (LSE:PHC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Plant Health Care (LSE:PHC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024